Weight | 1 lbs |
---|---|
Dimensions | 9 × 5 × 2 in |
accession | Q9Y337 |
express system | HEK293 |
product tag | C-His |
purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
background | The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches. |
molecular weight | The protein has a predicted MW of 30.7 kDa. Due to glycosylation, the protein migrates to 42-48 kDa based on Tris-Bis PAGE result. |
available size | 100 µg, 500 µg |
endotoxin | Less than 1EU per μg by the LAL method. |
Human Kallikrein 5/KLK5 Protein 3739
$300.00 – $1,000.00
Summary
- Expression: HEK293
- Functional: Yes (ELISA)
- Amino Acid Range: Val23-Ser293
Human Kallikrein 5/KLK5 Protein 3739
protein |
---|
Size and concentration 100, 500µg and lyophilized |
Form Lyophilized |
Storage Instructions Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
Storage buffer Shipped at ambient temperature. |
Purity > 95% as determined by Tris-Bis PAGE |
target relevance |
---|
The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches. |
Protein names Kallikrein-5 (EC 3.4.21.-) (Kallikrein-like protein 2) (KLK-L2) (Stratum corneum tryptic enzyme) |
Gene names KLK5,KLK5 SCTE UNQ570/PRO1132 |
Protein family Peptidase S1 family, Kallikrein subfamily |
Mass 32020Da |
Function May be involved in desquamation. |
Subellular location Secreted. |
Tissues Expressed in skin, breast, brain and testis. Expressed at the stratum granulosum of palmar skin. |
Structure Interacts with SPINK9. |
Target Relevance information above includes information from UniProt accession: Q9Y337 |
The UniProt Consortium |
Data
Publications
Publications
pmid | title | authors | citation |
---|---|---|---|
We haven't added any publications to our database yet. |
Protocols
relevant to this product |
---|
Documents
# | ||
---|---|---|
Please enter your product and batch number here to retrieve product datasheet, SDS, and QC information. |